Recombinant Human PSMA/FOLH1/NAALADase I His Avi Protein, CF

When Human PSMA/FOLH1/NAALADase I Affinity Purified Polyclonal Antibody (AF4234) is immobilized at 2 μg/mL, 100 μL/well, it binds Biotinylated Recombinant Human PSMA/FOLH1/NAALADase I His-tag Avi-tag with an ED50 of 0.01-0.08 μg/mL.

2 μg/lane of Biotinylated Recombinant Human PSMA/FOLH1/NAALADase I His-tag Avi-tag (Catalog # AVI4234) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at kDa.

• Reactivity: Hu
• Applications: Bioactivity, Enzyme Activity
• Format: Carrier-Free

Recombinant Human PSMA/FOLH1/NAALADase I His Avi Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Human PSMA/FOLH1 Affinity Purified Polyclonal Antibody (Catalog # AF4234) is immobilized at 2 μg/mL, 100 μL/well, it binds Biotinylated Recombinant Human PSMA/FOLH1/NAALADase I His-tag Avi-tag with an ED₅₀ of 0.01-0.08 μg/mL. Measured by its ability to hydrolyze the substrate N-acetyl-L-Asp-L-Glu into N-acetyl-L-Asp and L-Glu. The L-Glu product is measured by fluorescence after its derivatization by ortho-phthaldialdehyde. The specific activity is > 250 pmol/min/μg, as measured under the described conditions.
• Source: Chinese Hamster Ovary cell line, CHO-derived human PSMA/FOLH1/NAALADase I protein
  

  Avi-tag	HHHHHH	Human PSMA/FOLH1/NAALADase I (Lys44-Ala750) Accession # Q04609.1
  N-terminus		C-terminus

• Accession #: Q04609.1
• N-terminal Sequence: Gly
• Structure / Form: Biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Enzymes
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Enzyme Activity
• Theoretical MW: 83 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 94-107 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in MES and NaCl.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human PSMA/FOLH1/NAALADase I His Avi Protein, CF

• Cell growth-inhibiting gene 27 protein
• cell growth-inhibiting protein 27
• EC 3.4.17.21
• FGCP
• folate hydrolase (prostate-specific membrane antigen) 1
• Folate hydrolase 1
• FOLH1
• FOLHNAALADase I
• Folylpoly-gamma-glutamate carboxypeptidase
• GCP2
• GCPII
• GCPIImGCP
• glutamate carboxylase II
• glutamate carboxypeptidase 2
• Glutamate carboxypeptidase II
• Membrane glutamate carboxypeptidase
• mopsm
• NAALAD1
• NAALAD1N-acetylated-alpha-linked acidic dipeptidase I
• NAALADase I
• NAALAdase
• N-acetylated alpha-linked acidic dipeptidase 1
• prostate specific membrane antigen variant F
• Prostate-specific membrane antigen
• PSMA
• PSMAFGCP
• PSMPteroylpoly-gamma-glutamate carboxypeptidase

Background

Prostate-specific membrane antigen (PSMA), a tumor marker in prostate cancer encoded by the FOLH1 gene, is a type II transmembrane zinc metallopeptidase that is most highly expressed in the nervous system, prostate, kidney, and small intestine (1,2). PMSA has a short cytosolic N-terminal domain, a single membrane-spanning segment, and an extracellular region that is composed of a protease domain, apical domain, and C-terminal domain (3). The extracellular domains all contribute to substrate recognition. The protein forms an active homodimer reliant on interactions between amino-acid side chains and glycosylation (3,4). PSMA is also known as glutamate carboxypeptidase II (GCPII), folate hydrolase 1, and N-acetylated-alpha-linked acidic dipeptidase-1 (NAALADase1). PSMA activity plays a role in tumor angiogenesis making it not only a tumor marker, but a therapeutic target in cancers including prostate cancer (5). In the brain, PSMA hydrolyzes the neurotransmitter N-acetyl-Asp-Glu (NAAG) to produce glutamate, another neurotransmitter. Inhibition of brain PSMA activity is considered to be a promising approach for the treatment of neurological disorders associated with glutamate excitotoxicity such as stroke, schizophrenia, Alzheimer's, and amyotrophic lateral sclerosis (6,7,8). Intestinal PSMA hydrolyzes folylpoly-gamma -glutamates, facilitating the uptake of folate (8). Upregulation of PSMA is present in inflammatory bowel disease, Crohn's disease, and ulcerative colitis where pharmacological inhibition has shown amelioration of clinical symptoms pertaining to these diseases in mice (5).

1. Silver, D.A. et al. (1997) Clin. Cancer Res. 3:81.
   
2. Carter, R.E. et al. (1996) Pro. Natl. Acad. Sci. USA. 93:749.
3. Mesters, J.R. et al. (2006) EMBO J. 25:1375.
4. Shulke, N. et al. (2003) Proc. Natl. Acad. Sci. USA 100:12590.
5. Vornov, J.J. et al. (2019) Neurochem. Res. 45:1256. 
6. Jackson, P.F. and Slusher, B.S. (2001) Curr. Med. Chem. 8:949.
7. Neale, J. J and T. Yamamoto. (2020) Prog. Neurobiol. 184:101722.
8. Heston, W.D. (1997) Urology 49:104.

Bioinformatics

• Uniprot:
  • Q04609.1()